$8.27
+0.01 (+0.12%)
Open$8.31
Previous Close$8.26
Day High$8.39
Day Low$8.15
52W High$17.44
52W Low$6.01
Volume—
Avg Volume90.1K
Market Cap77.89M
P/E Ratio—
EPS$-13.02
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+75.8% upside
Current
$8.27
$8.27
Target
$14.54
$14.54
$12.76
$14.54 avg
$24.66
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.25M | 5.50M | 4.94M |
| Net Income | 1.19M | 1.50M | 1.15M |
| Profit Margin | 22.6% | 27.2% | 23.3% |
| EBITDA | 2.24M | 2.36M | 2.10M |
| Free Cash Flow | 844.4K | 896.3K | 789.1K |
| Rev Growth | +6.7% | -8.7% | -5.9% |
| Debt/Equity | 0.59 | 0.52 | 0.49 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |